Martin David Harp

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Robert Osher, MD, sat down with David Hutton of Ophthalmology Times to discuss the Lifetime Achievement award he received from the European Society of Cataract and Refractive Surgeons.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

Meeting in Stockholm provides education, updates, and a taste of culture.

According to the company, the pilot study showed procedural feasibility of ophthalmic artery angioplasty in the treatment of vascular lesions associated with geographic atrophy (GA).

Visual acuity and macular anatomy were maintained, with some changes in fluid management.

Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.”

Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.

Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal

The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.

The non-diffractive, aspheric IOLs are the second generation of BVI’s ISOPURE family

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

The agreement with give Apotex exclusive rights in Canada for the commercialization of APP13007.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The trial will evaluate VRDN-001, an intravenously delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

The nOCT allows for detailed visualization of the brain's vascular anatomy.

Scott Xiao, co-founder and CEO of Luminopia, sat with Ophthalmology Times to discuss the PUPiL Registry and how the VR treatment for children with amblyopia works and can revolutionize amblyopia treatment.

4D-150 Is being evaluated in wet age-related macular degeneration (AMD).

This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.